PTGS2 and neoplasm: For this purpose, PAMAM G3 dendrimer was conjugated with 16 celecoxib molecules (COX-2 inhibitor), 15 molecules of Fmoc-L-Leucine (agonist of PPARγ) and one tumor-targeting biotin molecule (G3-BCL) [39].